Phio Pharmaceuticals Corp. (PHIO) shares are trading at higher $2.35.
To add more color to this target, the company’s high over the last year is $18.15 and the low is $1.60. Over the last 52 weeks, PHIO is down -81.46% while the S&P 500 is up 7.73%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
PHIO Return on Equity (ROE) is -81.50%, and its Return on Assets is -66.70%. All told, it is clear that, PHIO needs to be on your watchlist.
Find out when PHIO reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. PHIO has a short ratio of 0.03 and outstanding shares of 4.97M.
PHIO has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -11.97. Phio Pharmaceuticals Corp. PHIO also noted assets of $20.21 million at the end of the last quarter. Investors should also keep an eye on sector updates as PHIO has historically followed its peers on positive news.
All told, Phio Pharmaceuticals Corp. PHIO has strung together solid data and demonstrated underlying fundamentals. At its current valuation, PHIO represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Phio Pharmaceuticals Corp. PHIO is now commanding a market cap of 13.86M and a float of 4.62M. PHIO is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of PHIO stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in PHIO, either long or short, and we have not been compensated for this article.